- CorMedix Inc CRMD stock is plunging after updating its resubmission timeline for the DefenCath marketing application.
- CorMedix has encountered delays at its third-party contract manufacturer.
- The Company was informed by the CMO that there are issues that are unrelated to DefenCath manufacturing activities.
- The timeline for CorMedix and the CMO to address deficiencies at the facility required for resubmission of the DefenCath application is uncertain at this time.
- Earlier, the Company expected to resubmit the DefenCath application in Q4 of 2021.
- Price Action: CRMD shares are down 22.8% at $4.97 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
